XENE Overview
Upcoming Projects (XENE)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (XENE)
-
Assessing Xenon Pharmaceuticals Inc.'s XEN1101 for the Treatment of Moderate to Severe Major Depressive Disorder (MDD) with a focus on the NOVA trial data
Ticker: XENE
Executed On: Dec 06, 2023 at 04:30 PM EST -
A discussion of XEN1101 in adult focal epilepsy
Ticker: XENE
Executed On: Jun 22, 2022 at 03:30 PM EDT -
A look at XEN1101 potential in MDD
Ticker: XENE
Executed On: Jun 22, 2022 at 02:00 PM EDT
Upcoming & Overdue Catalysts (XENE)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (XENE)
-
Xenon Pharma's (XENE) XEN1101 TMS Pharmacodynamic Phase 1 Data in epilepsy released
Ticker: XENE
Occurred on: May 15, 2018 -
Phase 2 data of TV-45070 for Postherpetic neuralgia due 1H 2017
Tickers: XENE, TEVA
Occurred on: Jun 27, 2017 -
Xenon (XENE) Phase 2 Topline Results for XEN801 in Moderate-to-Severe Acne
Ticker: XENE
Occurred on: Mar 24, 2017 -
Xenon Pharmaceuticals expects to file an investigational new drug (IND) application for XEN801 in the first half of 2017 - Discontinued
Ticker: XENE
Occurred on: Mar 24, 2017 -
Xenon Initiates Phase 2 Clinical Trial of XEN801 to Treat Moderate to Severe Acne
Ticker: XENE
Occurred on: Feb 10, 2016
Strategic Initiatives (XENE)
-
Neurocrine Biosciences (NBIX) and Xenon Pharmaceuticals(XENE) Announce Agreement to Develop First-in-Class Treatments for Epilepsy
Tickers: NBIX, XENE
Announcement Date: Dec 02, 2019
